Biblio
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet [Internet]. 2011;378:1779-1787. Available from: http://www.hubmed.org/display.cgi?uids=22047971
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry [Internet]. 2010. Available from: http://www.hubmed.org/display.cgi?uids=20562430
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther [Internet]. 2009;31:1724-1736. Available from: http://www.hubmed.org/display.cgi?uids=19808131
Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat Immunol [Internet]. 2007;8:817-824. Available from: http://www.hubmed.org/display.cgi?uids=17618287

]